Supaglutide Alleviates Hepatic Steatosis in Monkeys with Spontaneous MASH

Overview

Journal Diabetol Metab Syndr

Publisher Biomed Central

Specialty Endocrinology

Date 2024 Dec 19

PMID 39695722

Authors

Qinghua Wang

Yue Zhou

Yunzhi Ni

Zhihong Wang

Yan-Ru Lou

Zunyuan Yang

Li Gong

Yinan Liang

Wen Zeng

Gerald J Prudhomme

Affiliations

Soon will be listed here.

Abstract

Background: Glucagon-like peptide 1 (GLP-1) is an incretin hormone and plays an important role in regulating glucose homeostasis. GLP-1 has a short half-life due to degrading enzyme dipeptidyl peptidase-IV and rapid kidney clearance, which limits its clinical application as a therapeutic agent. We demonstrated previously that supaglutide, a novel long-acting GLP-1 analog, exerted hypoglycemic, hypolipidemic, and weight loss effects in type 2 diabetic db/db mice, DIO mice, and diabetic monkeys. In the present study, we investigated supaglutide's therapeutic efficacy in rhesus monkeys with spontaneous metabolic dysfunction-associated steatohepatitis (MASH).

Methods: 15 rhesus monkeys with biopsy-confirmed MASH were divided into three groups, receiving supaglutide 50 µg/kg, supaglutide 150 µg/kg, and placebo, respectively, by weekly subcutaneous injection for 3 months. Liver fat content quantified by magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF), liver pathology, and metabolic parameters were assessed.

Results: We found that once-weekly subcutaneous injections of supaglutide for 3 months significantly reduced hepatic fat accumulation, with a 40% percentage decrease in MRI-PDFF from baseline (P < 0.001 vs. Placebo). Treatment with supaglutide alleviated hepatic histological steatosis (nonalcoholic fatty liver disease activity score P < 0.001 vs. Placebo) without worsening of fibrosis, as assessed by ultrasound-guided liver biopsy. Supaglutide concomitantly ameliorated liver injury exemplified by a lowering tendency of hepatic alanine aminotransferase levels. Supaglutide also decreased body weight in a dose-dependent fashion accompanied by decreased food intake, improved lipid profile and glycemic control.

Conclusions: Supaglutide exerts beneficial effects on hepatic and metabolic outcomes in spontaneous MASH monkeys.

References

Trevaskis J, Griffin P, Wittmer C, Neuschwander-Tetri B, Brunt E, Dolman C . Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol. 2012; 302(8):G762-72. DOI: 10.1152/ajpgi.00476.2011. View

Qian C, Gong L, Yang Z, Chen W, Chen Y, Xu Z . Diastolic dysfunction in spontaneous type 2 diabetes rhesus monkeys: a study using echocardiography and magnetic resonance imaging. BMC Cardiovasc Disord. 2015; 15:59. PMC: 4480511. DOI: 10.1186/s12872-015-0046-9. View

Ohki T, Isogawa A, Iwamoto M, Ohsugi M, Yoshida H, Toda N . The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ScientificWorldJournal. 2012; 2012:496453. PMC: 3425807. DOI: 10.1100/2012/496453. View

Kawaguchi T, Itou M, Taniguchi E, Sata M . Exendin‑4, a glucagon‑like peptide‑1 receptor agonist, modulates hepatic fatty acid composition and Δ‑5‑desaturase index in a murine model of non‑alcoholic steatohepatitis. Int J Mol Med. 2014; 34(3):782-7. DOI: 10.3892/ijmm.2014.1826. View

Stanford K, Middelbeek R, Townsend K, An D, Nygaard E, Hitchcox K . Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J Clin Invest. 2012; 123(1):215-23. PMC: 3533266. DOI: 10.1172/JCI62308. View

Thoma C, Day C, Trenell M . Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2011; 56(1):255-66. DOI: 10.1016/j.jhep.2011.06.010. View

Wan Y, Bao X, Huang J, Zhang X, Liu W, Cui Q . Novel GLP-1 Analog Supaglutide Reduces HFD-Induced Obesity Associated with Increased Ucp-1 in White Adipose Tissue in Mice. Front Physiol. 2017; 8:294. PMC: 5430033. DOI: 10.3389/fphys.2017.00294. View

Malhi H, Gores G . Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis. 2008; 28(4):360-9. PMC: 2908270. DOI: 10.1055/s-0028-1091980. View

Yao Y, Li Q, Wang W, Zhang J, Gao P, Xu Y . Glucagon-Like Peptide-1 Modulates Cholesterol Homeostasis by Suppressing the miR-19b-Induced Downregulation of ABCA1. Cell Physiol Biochem. 2018; 50(2):679-693. DOI: 10.1159/000494235. View

10.

Tan Y, Zhen Q, Ding X, Shen T, Liu F, Wang Y . Association between use of liraglutide and liver fibrosis in patients with type 2 diabetes. Front Endocrinol (Lausanne). 2022; 13:935180. PMC: 9399467. DOI: 10.3389/fendo.2022.935180. View

11.

Petit J, Cercueil J, Loffroy R, Denimal D, Bouillet B, Fourmont C . Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study. J Clin Endocrinol Metab. 2016; 102(2):407-415. DOI: 10.1210/jc.2016-2775. View

12.

Ren L, Cui Q, Liu W, Wang L, Liao Y, Feng Y . Novel GLP-1 Analog Supaglutide Stimulates Insulin Secretion in Mouse and Human Islet Beta-Cells and Improves Glucose Homeostasis in Diabetic Mice. Front Physiol. 2019; 10:930. PMC: 6670290. DOI: 10.3389/fphys.2019.00930. View

13.

Mills E, Harmon C, Jedrychowski M, Xiao H, Garrity R, Tran N . UCP1 governs liver extracellular succinate and inflammatory pathogenesis. Nat Metab. 2021; 3(5):604-617. PMC: 8207988. DOI: 10.1038/s42255-021-00389-5. View

14.

Shiomi M, Tanaka Y, Takada T, Otori K . Determining whether the effect of liraglutide on non-alcoholic fatty liver disease depends on reductions in the body mass index. JGH Open. 2020; 4(5):995-1001. PMC: 7578289. DOI: 10.1002/jgh3.12384. View

15.

Malmstrom H, Walldius G, Grill V, Jungner I, Gudbjornsdottir S, Hammar N . Fructosamine is a useful indicator of hyperglycaemia and glucose control in clinical and epidemiological studies--cross-sectional and longitudinal experience from the AMORIS cohort. PLoS One. 2014; 9(10):e111463. PMC: 4213035. DOI: 10.1371/journal.pone.0111463. View

16.

Suzuki A, Lymp J, Sauver J, Angulo P, Lindor K . Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int. 2006; 26(10):1209-16. DOI: 10.1111/j.1478-3231.2006.01362.x. View

17.

Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z . Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol. 2010; 54(6):1214-23. DOI: 10.1016/j.jhep.2010.09.032. View

18.

Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View

19.

Targher G, Byrne C, Lonardo A, Zoppini G, Barbui C . Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016; 65(3):589-600. DOI: 10.1016/j.jhep.2016.05.013. View

20.

Sharma S, Mells J, Fu P, Saxena N, Anania F . GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One. 2011; 6(9):e25269. PMC: 3177901. DOI: 10.1371/journal.pone.0025269. View